Open Triple Therapy for Chronic Obstructive Pulmonary Disease: Patterns of Prescription, Exacerbations and Healthcare Costs From a Large Italian Claims Database

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000156
• EU PAS number:
  EUPAS1000000156
• Study ID:
  1000000156
• Official title and acronym:
  Open Triple Therapy for Chronic Obstructive Pulmonary Disease: Patterns of Prescription, Exacerbations and Healthcare Costs From a Large Italian Claims Database
• DARWIN EU® study:
  No
• Study countries:
  Italy
• Study description:
  An observational retrospective non-interventional cohort study of administrative halthcare data aimed to identify subjects with chronic obstructive pulmonary disease (COPD) treated with extemporaneous combination of inhaled corticosteroids (ICS)/long-actingβ2-agonist (LABA) and long-acting muscarinic antagonist (LAMA), namely open TT, and to describe the pharmacological strategy, the spirometry use, the exacerbations occurrence and the costs reimbursed by the Italian National Health System (SSN) in 1-year follow-up.
• Study status:
  Finalised

Research institutions and networks

Institutions

Fondazione ReS (Ricerca e Salute), CINECA partner

Italy

Study timelines

Date when funding contract was signed

Actual: 08/01/2019

Study start date

Actual: 08/02/2019

Date of final study report

Actual: 08/05/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

This research received the unconditional support of Glaxo Smith Kline, which did not have a role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication. The grant number is not available.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable